Thomas McRae

4.3k total citations · 1 hit paper
47 papers, 2.5k citations indexed

About

Thomas McRae is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Thomas McRae has authored 47 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 15 papers in Psychiatry and Mental health and 9 papers in Pharmacology. Recurrent topics in Thomas McRae's work include Smoking Behavior and Cessation (16 papers), Dementia and Cognitive Impairment Research (12 papers) and Nicotinic Acetylcholine Receptors Study (8 papers). Thomas McRae is often cited by papers focused on Smoking Behavior and Cessation (16 papers), Dementia and Cognitive Impairment Research (12 papers) and Nicotinic Acetylcholine Receptors Study (8 papers). Thomas McRae collaborates with scholars based in United States, United Kingdom and Canada. Thomas McRae's co-authors include Robert West, Cristina Russ, Robert M. Anthenelli, David Lawrence, Neal L. Benowitz, A. Eden Evins, Alok Krishen, Robert A. Murden, John A. Ascher and John R. Ieni and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Thomas McRae

44 papers receiving 2.4k citations

Hit Papers

Neuropsychiatric safety and efficacy of varenicline, bupr... 2016 2026 2019 2022 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    2016 632 citations Robert M. Anthenelli, Neal L. Benowitz et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas McRae United States 22 1.2k 846 433 385 329 47 2.5k
Suzanne L. Tyas Canada 29 1.3k 1.1× 930 1.1× 507 1.2× 94 0.2× 150 0.5× 83 3.4k
Kai G. Kahl Germany 28 897 0.8× 747 0.9× 231 0.5× 221 0.6× 195 0.6× 118 3.5k
Nicola Coley France 29 800 0.7× 1.3k 1.5× 396 0.9× 203 0.5× 142 0.4× 85 2.7k
Valory Pavlik United States 30 484 0.4× 487 0.6× 524 1.2× 145 0.4× 234 0.7× 87 3.7k
Deborah B. Marin United States 31 870 0.7× 1.2k 1.5× 324 0.7× 364 0.9× 190 0.6× 73 2.9k
Patricia Schofield United Kingdom 26 873 0.8× 406 0.5× 384 0.9× 320 0.8× 94 0.3× 80 2.7k
Pekka Mäntyselkä Finland 30 576 0.5× 407 0.5× 432 1.0× 709 1.8× 279 0.8× 128 3.2k
Mary de Groot United States 30 504 0.4× 604 0.7× 356 0.8× 193 0.5× 126 0.4× 81 6.4k
Margaret E. Mattson United States 29 720 0.6× 549 0.6× 915 2.1× 670 1.7× 292 0.9× 60 5.4k
Johan Detraux Belgium 22 772 0.7× 3.1k 3.7× 292 0.7× 305 0.8× 258 0.8× 41 5.4k

Countries citing papers authored by Thomas McRae

Since Specialization
Citations

This map shows the geographic impact of Thomas McRae's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas McRae with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas McRae more than expected).

Fields of papers citing papers by Thomas McRae

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas McRae. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas McRae. The network helps show where Thomas McRae may publish in the future.

Co-authorship network of co-authors of Thomas McRae

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas McRae. A scholar is included among the top collaborators of Thomas McRae based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas McRae. Thomas McRae is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dunne, Richard F., Jeffrey Crawford, Karen E. Smoyer, et al.. (2024). The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review. Journal of Cachexia Sarcopenia and Muscle. 15(5). 1628–1640. 4 indexed citations
2.
3.
Gorgis, Sarah, Alejandro Lemor, Thomas McRae, et al.. (2024). Impact of Right Ventricular Dysfunction on Outcomes in Acute Myocardial Infarction and Cardiogenic Shock: Insights from the National Cardiogenic Shock Initiative. Journal of Cardiac Failure. 30(10). 1275–1284. 1 indexed citations
4.
McKee, Sherry A., et al.. (2023). Sex effects in predictors of smoking abstinence and neuropsychiatric adverse events in the EAGLES trial. SHILAP Revista de lepidopterología. 8. 100177–100177. 4 indexed citations
5.
Basir, Mir, Sarah Gorgis, Alejandro Lemor, et al.. (2020). TCT CONNECT-176 Diastolic Suction Alarms Are an Early Marker for Right Ventricular Failure in the Setting of Left Ventricular Mechanical Circulatory Support. Journal of the American College of Cardiology. 76(17). B76–B76. 2 indexed citations
6.
Ayers, Catherine R., Jaimee L. Heffner, Cristina Russ, et al.. (2019). Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active‐ and placebo‐controlled EAGLES trial. Depression and Anxiety. 37(3). 247–260. 13 indexed citations
7.
Benowitz, Neal L., Andrew Pipe, Robert West, et al.. (2018). Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. JAMA Internal Medicine. 178(5). 622–622. 93 indexed citations
8.
Ivanoiu, Adrian, Jérémie Pariente, Kevin Booth, et al.. (2016). Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies. Alzheimer s Research & Therapy. 8(1). 24–24. 33 indexed citations
9.
Anthenelli, Robert M., Neal L. Benowitz, Robert West, et al.. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 387(10037). 2507–2520. 632 indexed citations breakdown →
10.
Gonzales, David, et al.. (2014). Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics. 96(3). 390–396. 34 indexed citations
11.
Kishnani, Priya S., James H. Heller, Gail A. Spiridigliozzi, et al.. (2010). Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. American Journal of Medical Genetics Part A. 152A(12). 3028–3035. 63 indexed citations
12.
Schmitt, Frederick A., Judith Saxton, Yikang Xu, et al.. (2009). A Brief Instrument to Assess Treatment Response in the Patient With Advanced Alzheimer Disease. Alzheimer Disease & Associated Disorders. 23(4). 377–383. 14 indexed citations
13.
Mucha, Lisa, et al.. (2008). Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease. Journal of Managed Care Pharmacy. 14(5). 451–461. 53 indexed citations
14.
Keohane, Denis, et al.. (2006). Patterns of cholinesterase-inhibitor use in the nursing home setting: A retrospective analysis. ˜The œAmerican journal of geriatric pharmacotherapy. 4(2). 154–160. 27 indexed citations
15.
Wimo, Anders, et al.. (2004). Impact of donepezil treatment for Alzheimer's disease on caregiver time. Current Medical Research and Opinion. 20(8). 1221–1225. 33 indexed citations
16.
Finkel, Sanford I., Jacobo Mintzer, Maurice W. Dysken, et al.. (2004). A randomized, placebo‐controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. International Journal of Geriatric Psychiatry. 19(1). 9–18. 116 indexed citations
17.
Geldmacher, David, George Provenzano, Thomas McRae, Vera Mastey, & John R. Ieni. (2003). Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease. Journal of the American Geriatrics Society. 51(7). 937–944. 216 indexed citations
18.
Relkin, Norman, William E. Reichman, John Orazem, & Thomas McRae. (2003). A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 16(1). 15–24. 35 indexed citations
19.
Aronow, Herbert D., Thomas McRae, Eric J. Topol, et al.. (2002). Patients on lipid-lowering therapy at the time of a myocardial infarction have smaller infarcts: further evidence to suggest a salutary effect in acute coronary syndromes. Journal of the American College of Cardiology. 39. 318–318. 4 indexed citations
20.
Murden, Robert A., et al.. (1991). Mini‐Mental State Exam Scores Vary with Education in Blacks and Whites. Journal of the American Geriatrics Society. 39(2). 149–155. 258 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne L. Tyas Breakdown of academic impact, for papers by Kai G. Kahl Breakdown of academic impact, for papers by Nicola Coley Breakdown of academic impact, for papers by Valory Pavlik Breakdown of academic impact, for papers by Deborah B. Marin Breakdown of academic impact, for papers by Patricia Schofield Breakdown of academic impact, for papers by Pekka Mäntyselkä Breakdown of academic impact, for papers by Mary de Groot Breakdown of academic impact, for papers by Margaret E. Mattson Breakdown of academic impact, for papers by Johan Detraux
Rankless by CCL
2026